228670.KQ
Ray Co., Ltd.
KOE · Healthcare · Medical - Specialties · KR
KRW 4,795.00
−0.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 119.1B | 111.2B | 79.8B | 145.9B | 129.0B |
| Cost of Revenue | 69.2B | 65.1B | 43.8B | 80.8B | 69.9B |
| Gross Profit | 49.8B | 46.1B | 36.0B | 65.1B | 59.1B |
| Operating Expenses | |||||
| R&D Expense | 6.1B | 6.3B | 6.6B | 7.0B | 6.2B |
| SG&A Expense | 23.5B | 17.1B | 15.0B | 19.2B | 12.5B |
| General & Admin Expense | 10.9B | 5.3B | 3.5B | 6.6B | 4.0B |
| Selling & Marketing Expense | 12.6B | 11.7B | 11.6B | 12.6B | 8.5B |
| Other Expenses | 26.2B | 32.7B | 58.6B | 32.8B | 24.2B |
| Total Operating Expenses | 55.8B | 56.0B | 80.3B | 59.0B | 42.9B |
| Cost and Expenses | 125.1B | 121.1B | 124.1B | 139.8B | 112.8B |
| Operating Income (EBIT) | (5.9B) | (9.8B) | (44.3B) | 6.1B | 16.2B |
| Non-Operating | |||||
| Interest Income | 399.9M | 519.4M | 625.1M | 459.4M | 631.2M |
| Interest Expense | 6.5B | 6.5B | 5.3B | 3.2B | 2.7B |
| Net Interest Income | (6.1B) | (6.0B) | (4.6B) | (2.8B) | (2.1B) |
| Other Non-Op Income/Expense | 12.7B | 11.1B | (12.0B) | (10.4B) | (4.7B) |
| Non-Operating Income (excl Interest) | (14.2B) | — | 6.7B | 7.1B | 2.9B |
| EBT (Pre-Tax Income) | 6.8B | 1.3B | (56.2B) | (4.2B) | 11.5B |
| Income Tax Expense | (39.2M) | 873.0M | 7.1B | (1.2B) | 3.5B |
| Bottom Line | |||||
| Net Income | 9.6B | 3.1B | (60.4B) | (2.1B) | 8.0B |
| Earnings from Cont. Ops | 7.2B | 467.2M | (61.1B) | (3.0B) | 8.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 9.6B | 3.1B | (60.4B) | (2.1B) | 8.0B |
| Per Share | |||||
| Basic EPS | ₩614 | ₩201 | (₩3,863) | (₩140) | ₩541 |
| Diluted EPS | ₩533 | ₩201 | (₩3,863) | (₩140) | ₩539 |
| Revenue Per Share | ₩7,614 | ₩7,129 | ₩5,104 | ₩9,533 | ₩8,770 |
| Shares | |||||
| Basic Shares Outstanding | 15.6M | 15.6M | 15.6M | 15.3M | 14.7M |
| Diluted Shares Outstanding | 15.6M | 15.6M | 15.6M | 15.3M | 14.8M |
| Profitability Metrics | |||||
| EBITDA | 18.0B | (663.4M) | (40.2B) | 7.6B | 22.5B |
| D&A | 8.8B | 9.1B | 8.6B | 8.6B | 6.3B |
| EBIT | 9.2B | (9.8B) | (48.7B) | (1.0B) | 16.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026